Share Wealth

Market
  • Markets Navigation
    Company Info.

    Cohance Lifesciences Ltd.

    Ratio Analysis - Consolidated


    Market Cap.(`) 27696.67 Cr. P/BV 14.00 Book Value (`) 77.71
    52 Week High/Low ( ` ) 1360/598 FV/ML 1/1 P/E(X) 92.24
    Book Closure 09/08/2024 EPS (`) 11.80 Div Yield (%) 0.00


    You can view the Consolidated Ratio Analysis for the last 5 years.

    ParticularsMar 24Mar 23Mar 22Mar 21Mar 20
    Months1212121212
    Source Of Info (AR = Annual Report, PR = Press Release)ARARARARAR
    FaceValue1.001.001.001.001.00
          
    PER SHARE RATIOS     
          
    Basic EPS (Rs.)11.8016.1617.8314.2324.91
    Diluted EPS (Rs.)11.8016.1617.8314.2324.91
    Cash EPS (Rs.)13.9418.0317.7513.3722.99
    Book Value[Excl.RevalReserv]/Share (Rs.)80.5668.1659.9946.3966.37
    Book Value[Incl.RevalReserv]/Share (Rs.)80.5668.1659.9946.3966.37
    Revenue From Operations / Share (Rs.)41.3052.6551.8639.6665.51
    PBDIT / Share (Rs.)18.3724.0826.3917.8631.68
    PBIT / Share (Rs.)16.2322.2024.8516.6229.81
    PBT / Share (Rs.)15.9421.9924.6116.2627.99
    Net Profit / Share (Rs.)11.8016.1616.2112.1221.12
    NP After MI And SOA / Share (Rs.)11.8016.1617.8314.2324.91
          
    PROFITABILITY RATIOS     
          
    PBDIT Margin (%)44.4845.7250.8845.0348.36
    PBIT Margin (%)39.2942.1647.9241.9045.49
    PBT Margin (%)38.5841.7647.4540.9942.73
    Net Profit Margin (%)28.5630.6831.2530.5632.23
    NP After MI And SOA Margin (%)28.5630.6834.3735.8838.01
    Return on Networth / Equity (%)14.6423.7029.7130.6837.52
    Return on Capital Employeed (%)19.2431.2739.0733.7139.01
    Return On Assets (%)13.3220.9224.8024.5727.02
    Long Term Debt / Equity (X)0.000.000.010.030.10
    Total Debt / Equity (X)0.010.040.060.110.21
    Asset Turnover Ratio (%)0.490.700.800.790.88
          
    LIQUIDITY RATIOS     
          
    Current Ratio (X)11.826.375.362.571.95
    Quick Ratio (X)9.654.404.021.661.08
    Inventory Turnover Ratio (X)0.971.441.901.651.45
    Dividend Payout Ratio (NP) (%)0.0049.5122.437.0220.07
    Dividend Payout Ratio (CP) (%)0.0044.3620.656.4618.67
    Earning Retention Ratio (%)0.0050.4977.5792.9879.93
    Cash Earning Retention Ratio (%)0.0055.6479.3593.5481.33
          
    COVERAGE RATIOS     
          
    Interest Coverage Ratio (%)62.77112.74107.8249.7317.48
    Interest Coverage Ratio (Post Tax) (%)41.3076.6667.2334.7512.65
          
    VALUATION RATIOS     
          
    Enterprise Value (Cr.)17211.9412039.3615779.1112742.732735.31
    EV / Net Operating Revenue (X)16.378.9811.9512.623.28
    EV / EBITDA (X)36.8019.6423.4928.026.78
    MarketCap / Net Operating Revenue (X)16.388.9811.9212.493.08
    Retention Ratios (%)0.0050.4877.5692.9779.92
    Price / BV (X)8.406.9310.3010.683.04
    Price / Net Operating Revenue (X)16.388.9811.9212.493.08
    EarningsYield0.010.030.020.020.12

  • Cohance Lifesciences Ltd.

    Cash Flow - Consolidated


    Market Cap.(`) 27696.67 Cr. P/BV 14.00 Book Value (`) 77.71
    52 Week High/Low ( ` ) 1360/598 FV/ML 1/1 P/E(X) 92.24
    Book Closure 09/08/2024 EPS (`) 11.80 Div Yield (%) 0.00


    (` in Crs.)
    You can view the Consolidated Cash Flow for the last 5 years.

    ParticularsMar 24Mar 23Mar 22Mar 21Mar 20
    Months1212121212
    Source Of Info (AR = Annual Report, PR = Press Release)ARARARARAR
    FaceValue1.001.001.001.001.00
          
    Net Profit/Loss Before Extraordinary Items And Tax405.67559.73667.59467.67404.51
          
    Net CashFlow From Operating Activities358.48450.91330.00383.44415.95
    Net Cash Used In Investing Activities-362.25-194.84-136.21-311.40-421.53
    Net Cash Used From Financing Activities-13.80-235.83-156.41-76.556.37
          
    Net Inc/Dec In Cash And Cash Equivalents-17.5720.2437.38-4.510.79
    Cash And Cash Equivalents Begin of Year64.8044.567.1811.7010.90
    Cash And Cash Equivalents End Of Year47.2364.8044.567.1811.70
Attention Investors : “Prevent unauthorized transactions in your account ? Update your Mobile Numbers/Email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your Mobile/Email at the end of the day. Issued in the interest of Investors” ***** No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorize your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.   |     |  ***** KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.   |  "Revised guidelines on margin collection ==> 1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. | 2. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. | 3. Pay 20% upfront margin of the transaction value to trade in cash market segment. | 4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. | 5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month. .......... Issued in the interest of Investors"   |  ***** MEMBERS : SEBI Regn. No: NSE, BSE: INZ000176636 ; MCX : INZ000057535; SEBI Research Analyst Regn No: INH200000337; AMFI Regn No. 77624; Depository Participant : CDSL : IN-DP-CDSL-379-2006 DP ID : 12047600   |  For any Grievance mail to : grievance@sharewealthindia.com   |  For any DP Grievance mail to : dpgrievance@sharewealthindia.com.   |  Grievance with SEBI : https://scores.gov.in/scores/Welcome.html